Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles

IntroductionImproved therapies for glioblastoma (GBM) are desperately needed and require preclinical evaluation in models that capture tumor heterogeneity and intrinsic resistance seen in patients. Epigenetic alterations have been well documented in GBM and lysine-specific demethylase 1 (LSD1/KDM1A)...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Lea M. Stitzlein, Achintyan Gangadharan, Leslie M. Walsh, Deokhwa Nam, Alexsandra B. Espejo, Melissa M. Singh, Kareena H. Patel, Yue Lu, Xiaoping Su, Ravesanker Ezhilarasan, Joy Gumin, Sanjay Singh, Erik Sulman, Frederick F. Lang, Joya Chandra
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2023-04-01
Ráidu:	Frontiers in Neurology
Fáttát:	histone demethylase inhibitors epigenetics lysine specific demethylase (KDM) glioblastoma drug resistance
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1112207/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!